Role of biomarkers in the management of antibiotic therapy: an expert panel review II: clinical use of biomarkers for initiation or discontinuation of antibiotic therapy.
[en] Biomarker-guided initiation of antibiotic therapy has been studied in four conditions: acute pancreatitis, lower respiratory tract infection (LRTI), meningitis, and sepsis in the ICU. In pancreatitis with suspected infected necrosis, initiating antibiotics best relies on fine-needle aspiration and demonstration of infected material. We suggest that PCT be measured to help predict infection; however, available data are insufficient to decide on initiating antibiotics based on PCT levels. In adult patients suspected of community-acquired LRTI, we suggest withholding antibiotic therapy when the serum PCT level is low (<0.25 ng/mL); in patients having nosocomial LRTI, data are insufficient to recommend initiating therapy based on a single PCT level or even repeated measurements. For children with suspected bacterial meningitis, we recommend using a decision rule as an aid to therapeutic decisions, such as the Bacterial Meningitis Score or the Meningitest(R); a single PCT level >/=0.5 ng/mL also may be used, but false-negatives may occur. In adults with suspected bacterial meningitis, we suggest integrating serum PCT measurements in a clinical decision rule to help distinguish between viral and bacterial meningitis, using a 0.5 ng/mL threshold. For ICU patients suspected of community-acquired infection, we do not recommend using a threshold serum PCT value to help the decision to initiate antibiotic therapy; data are insufficient to recommend using PCT serum kinetics for the decision to initiate antibiotic therapy in patients suspected of ICU-acquired infection. In children, CRP can probably be used to help discontinue therapy, although the evidence is limited. In adults, antibiotic discontinuation can be based on an algorithm using repeated PCT measurements. In non-immunocompromised out- or in- patients treated for RTI, antibiotics can be discontinued if the PCT level at day 3 is < 0.25 ng/mL or has decreased by >80-90%, whether or not microbiological documentation has been obtained. For ICU patients who have nonbacteremic sepsis from a known site of infection, antibiotics can be stopped if the PCT level at day 3 is < 0.5 ng/mL or has decreased by >80% relative to the highest level recorded, irrespective of the severity of the infectious episode; in bacteremic patients, a minimal duration of therapy of 5 days is recommended.
Disciplines :
Anesthesia & intensive care
Author, co-author :
Quenot, Jean-Pierre
Luyt, Charles-Edouard
Roche, Nicolas
Chalumeau, Martin
Charles, Pierre-Emmanuel
Claessens, Yann-Eric
Lasocki, Sigismond
Bedos, Jean-Pierre
Pean, Yves
Philippart, Francois
Ruiz, Stephanie
Gras-Leguen, Christele
Dupuy, Anne-Marie
Pugin, Jerome
Stahl, Jean-Paul
Misset, Benoît ; Centre Hospitalier Universitaire de Liège - CHU > Service de Soins Intensifs
Role of biomarkers in the management of antibiotic therapy: an expert panel review II: clinical use of biomarkers for initiation or discontinuation of antibiotic therapy.
Mofidi R, Suttie SA, Patil PV, Ogston S, Parks RW: The value of procalcitonin at predicting the severity of acute pancreatitis and development of infected pancreatic necrosis: systematic review. Surgery 2009, 146:72-81.
Rau B, Steinbach G, Baumgart K, Gansauge F, Grunert A, Beger HG: The clinical value of procalcitonin in the prediction of infected necrosis in acute pancreatitis. Intensive Care Med 2000, 26(Suppl 2):S159-S164.
Morgenthaler NG, Struck J, Christ-Crain M, Bergmann A, Muller B: Pro-atrial natriuretic peptide is a prognostic marker in sepsis, similar to the APACHE II score: an observational study. Crit Care 2005, 9:R37-R45.
Rau B, Steinbach G, Gansauge F, Mayer JM, Grunert A, Beger HG: The potential role of procalcitonin and interleukin 8 in the prediction of infected necrosis in acute pancreatitis. Gut 1997, 41:832-840.
Riche FC, Cholley BP, Laisne MJ, Vicaut E, Panis YH, Lajeunie EJ, Boudiaf M, Valleur PD: Inflammatory cytokines, C reactive protein, and procalcitonin as early predictors of necrosis infection in acute necrotizing pancreatitis. Surgery 2003, 133:257-262.
Purkayastha S, Chow A, Athanasiou T, Cambaroudis A, Panesar S, Kinross J, Tekkis P, Darzi A: Does serum procalcitonin have a role in evaluating the severity of acute pancreatitis? A question revisited. World J Surg 2006, 30:1713-1721.
Lu Z, Liu Y, Dong YH, Zhan XB, Du YQ, Gao J, Gong YF, Li ZS: Soluble triggering receptor expressed on myeloid cells in severe acute pancreatitis: a biological marker of infected necrosis. Intensive Care Med 2012, 38:69-75.
Olah A, Belagyi T, Issekutz A, Makay R, Zaborszky A: Value of procalcitonin quick test in the differentiation between sterile and infected forms of acute pancreatitis. Hepatogastroenterology 2005, 52:243-245.
Mandi Y, Farkas G, Takacs T, Boda K, Lonovics J: Diagnostic relevance of procalcitonin, IL-6, and sICAM-1 in the prediction of infected necrosis in acute pancreatitis. Int J Pancreatol 2000, 28:41-49.
Muller CA, Uhl W, Printzen G, Gloor B, Bischofberger H, Tcholakov O, Buchler MW: Role of procalcitonin and granulocyte colony stimulating factor in the early prediction of infected necrosis in severe acute pancreatitis. Gut 2000, 46:233-238.
Evans AT, Husain S, Durairaj L, Sadowski LS, Charles-Damte M, Wang Y: Azithromycin for acute bronchitis: a randomised, double-blind, controlled trial. Lancet 2002, 359:1648-1654.
Poses RM, Cebul RD, Wigton RS: You can lead a horse to water-improving physicians' knowledge of probabilities may not affect their decisions. Med Decis Making 1995, 15:65-75.
Sabuncu E, David J, Bernede-Bauduin C, Pepin S, Leroy M, Boelle PY, Watier L, Guillemot D: Significant reduction of antibiotic use in the community after a nationwide campaign in France, 2002-2007. PLoS Med 2009, 6:e1000084.
Briel M, Christ-Crain M, Young J, Schuetz P, Huber P, Periat P, Bucher HC, Muller B: Procalcitonin-guided antibiotic use versus a standard approach for acute respiratory tract infections in primary care: study protocol for a randomised controlled trial and baseline characteristics of participating general practitioners [ISRCTN73182671]. BMC Fam Pract 2005, 6:34.
Briel M, Schuetz P, Mueller B, Young J, Schild U, Nusbaumer C, Periat P, Bucher HC, Christ-Crain M: Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med 2008, 168:2000-2007. discussion 2007-2008.
Burkhardt O, Ewig S, Haagen U, Giersdorf S, Hartmann O, Wegscheider K, Hummers-Pradier E, Welte T: Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. Eur Respir J 2010, 36:601-607.
Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, Muller B: Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004, 363:600-607.
Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, Huber PR, Zimmerli W, Harbarth S, Tamm M, Muller B: Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006, 174:84-93.
Kristoffersen KB, Sogaard OS, Wejse C, Black FT, Greve T, Tarp B, Storgaard M, Sodemann M: Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission-a randomized trial. Clin Microbiol Infect 2009, 15:481-487.
Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Muller C, Huber P, Muller B, Tamm M: Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007, 131:9-19.
Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, et al: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34:1589-1596.
Long W, Deng X, Zhang Y, Lu G, Xie J, Tang J: Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community-acquired pneumonia. Respirology 2011, 16:819-824.
Long W, Deng XQ, Tang JG, Xie J, Zhang YC, Zhang Y, Gao YY, Lu G: The value of serum procalcitonin in treatment of community acquired pneumonia in outpatient. Zhonghua Nei Ke Za Zhi 2009, 48:216-219.
Cals JW, Butler CC, Hopstaken RM, Hood K, Dinant GJ: Effect of point of care testing for C reactive protein and training in communication skills on antibiotic use in lower respiratory tract infections: cluster randomised trial. BMJ (Clinical research ed 2009:b1374.
Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, Neidert S, Fricker T, Blum C, Schild U, et al: Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009, 302:1059-1066.
Muller B, Becker KL, Schachinger H, Rickenbacher PR, Huber PR, Zimmerli W, Ritz R: Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med 2000, 28:977-983.
Albrich WC, Dusemund F, Bucher B, Meyer S, Thomann R, Kuhn F, Bassetti S, Sprenger M, Bachli E, Sigrist T, et al: Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in real life: an international, multicenter poststudy survey (ProREAL). Arch Intern Med 2012, 172:715-722.
Van Der Meer V, Neven AK, van den Broek PJ, Assendelft WJ: Diagnostic value of C reactive protein in infections of the lower respiratory tract: systematic review. BMJ (Clinical research ed 2005, 331:26.
Schuetz P, Chiappa V, Briel M, Greenwald JL: Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med 2011, 171:1322-1331.
Chenevier-Gobeaux C, Trabattoni E, Elfassy Y, Picard C, Guerin S, Borderie D, Claessens YE: Decisional procalcitonin thresholds are not adapted to elderly patients admitted to the emergency room. Biomarkers 2012, 17:477-481.
Schuetz P, Muller B, Christ-Crain M, Stolz D, Tamm M, Bouadma L, Luyt CE, Wolff M, Chastre J, Tubach F, et al: Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane database of systematic reviews (Online) 2012, 9:CD007498.
Schuetz P, Briel M, Christ-Crain M, Stolz D, Bouadma L, Wolff M, Luyt CE, Chastre J, Tubach F, Kristoffersen KB, et al: Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clin Infect Dis 2012, 55:651-662.
Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, Schortgen F, Lasocki S, Veber B, Dehoux M, et al: Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010, 375:463-474.
Layios N, Lambermont B, Canivet JL, Morimont P, Preiser JC, Garweg C, Ledoux D, Frippiat F, Piret S, Giot JB, et al: Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients. Crit Care Med 2012, 40:2304-2309.
Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J: Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 2008, 177:498-505.
Charles PE, Kus E, Aho S, Prin S, Doise JM, Olsson NO, Blettery B, Quenot JP: Serum procalcitonin for the early recognition of nosocomial infection in the critically ill patients: a preliminary report. BMC Infect Dis 2009, 9:49.
Nigrovic LE, Kuppermann N, Macias CG, Cannavino CR, Moro-Sutherland DM, Schremmer RD, Schwab SH, Agrawal D, Mansour KM, Bennett JE, et al: Clinical prediction rule for identifying children with cerebrospinal fluid pleocytosis at very low risk of bacterial meningitis. JAMA 2007, 297:52-60.
Dubos F, Lamotte B, Bibi-Triki F, Moulin F, Raymond J, Gendrel D, Breart G, Chalumeau M: Clinical decision rules to distinguish between bacterial and aseptic meningitis. Arch Dis Child 2006, 91:647-650.
Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, Whitley RJ: Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004, 39:1267-1284.
Khetsuriani N, Quiroz ES, Holman RC, Anderson LJ: Viral meningitis-associated hospitalizations in the United States, 1988-1999. Neuroepidemiology 2003, 22:345-352.
Gendrel D, Raymond J, Assicot M, Moulin F, Iniguez JL, Lebon P, Bohuon C: Measurement of procalcitonin levels in children with bacterial or viral meningitis. Clin Infect Dis 1997, 24:1240-1242.
Marc E, Menager C, Moulin F, Stos B, Chalumeau M, Guerin S, Lebon P, Brunet F, Raymond J, Gendrel D: Procalcitonin and viral meningitis: reduction of unnecessary antibiotics by measurement during an outbreak. Arch Pediatr 2002, 9:358-364.
Dubos F, Moulin F, Gajdos V, De Suremain N, Biscardi S, Lebon P, Raymond J, Breart G, Gendrel D, Chalumeau M: Serum procalcitonin and other biologic markers to distinguish between bacterial and aseptic meningitis. J Pediatr 2006, 149:72-76.
Dubos F, Korczowski B, Aygun DA, Martinot A, Prat C, Galetto-Lacour A, Casado-Flores J, Taskin E, Leclerc F, Rodrigo C, et al: Serum procalcitonin level and other biological markers to distinguish between bacterial and aseptic meningitis in children: a European multicenter case cohort study. Arch Pediatr Adolesc Med 2008, 162:1157-1163.
Nigrovic LE, Kuppermann N, Malley R: Development and validation of a multivariable predictive model to distinguish bacterial from aseptic meningitis in children in the post-Haemophilus influenzae era. Pediatrics 2002, 110:712-719.
Hoen B, Viel JF, Paquot C, Gerard A, Canton P: Multivariate approach to differential diagnosis of acute meningitis. Eur J Clin Microbiol Infect Dis 1995, 14:267-274.
Freedman SB, Marrocco A, Pirie J, Dick PT: Predictors of bacterial meningitis in the era after Haemophilus influenzae. Arch Pediatr Adolesc Med 2001, 155:1301-1306.
Oostenbrink R, Moons KG, Twijnstra MJ, Grobbee DE, Moll HA: Children with meningeal signs: predicting who needs empiric antibiotic treatment. Arch Pediatr Adolesc Med 2002, 156:1189-1194.
Bonsu BK, Harper MB: Differentiating acute bacterial meningitis from acute viral meningitis among children with cerebrospinal fluid pleocytosis: a multivariable regression model. Pediatr Infect Dis J 2004, 23:511-517.
Bingen E, Levy C, de la Rocque F, Boucherat M, Varon E, Alonso JM, Dabernat H, Reinert P, Aujard Y, Cohen R: Bacterial meningitis in children: a French prospective study. Clin Infect Dis 2005, 41:1059-1063.
Dubos F, De la Rocque F, Levy C, Bingen E, Aujard Y, Cohen R, Breart G, Gendrel D, Chalumeau M: Sensitivity of the bacterial meningitis score in 889 children with bacterial meningitis. J Pediatr 2008, 152:378-382.
Nigrovic LE, Malley R, Kuppermann N: Meta-analysis of bacterial meningitis score validation studies. Arch Dis Child 2012, 97:799-805.
Dubos F, Moulin F, Raymond J, Gendrel D, Breart G, Chalumeau M: Distinction between bacterial and aseptic meningitis in children: refinement of a clinical decision rule. Arch Pediatr 2007, 14:434-438.
Dubos F, Korczowski B, Aygun DA, Martinot A, Prat C, Galetto-Lacour A, Casado-Flores J, Taskin E, Leclerc F, Rodrigo C, et al: Distinguishing Quenotetal. AnnalsofIntensive Care 2013, 3:21 between bacterial and aseptic meningitis in children: European comparison of two clinical decision rules. Arch Dis Child 2010, 95:963-967.
Société de Pathologie Infectieuse de Langue Française (SPILF): Practice guidelines for acute bacterial meningitidis (except newborn and nosocomial meningitis). Med Mal Infect 2009, 39:356-367.
Baty V, Viel JF, Schuhmacher H, Jaeger F, Canton P, Hoen B: Prospective validation of a diagnosis model as an aid to therapeutic decision-making in acute meningitis. Eur J Clin Microbiol Infect Dis 2000, 19:422-426.
Knudsen TB, Larsen K, Kristiansen TB, Moller HJ, Tvede M, Eugen-Olsen J, Kronborg G: Diagnostic value of soluble CD163 serum levels in patients suspected of meningitis: comparison with CRP and procalcitonin. Scand J Infect Dis 2007, 39:542-553.
Ray P, Badarou-Acossi G, Viallon A, Boutoille D, Arthaud M, Trystram D, Riou B: Accuracy of the cerebrospinal fluid results to differentiate bacterial from non bacterial meningitis, in case of negative gram-stained smear. Am J Emerg Med 2007, 25:179-184.
Schwarz S, Bertram M, Schwab S, Andrassy K, Hacke W: Serum procalcitonin levels in bacterial and abacterial meningitis. Crit Care Med 2000, 28:1828-1832.
Viallon A, Desseigne N, Marjollet O, Birynczyk A, Belin M, Guyomarch S, Borg J, Pozetto B, Bertrand JC, Zeni F: Meningitis in adult patients with a negative direct cerebrospinal fluid examination: value of cytochemical markers for differential diagnosis. Crit Care 2011, 15:R136.
Gerdes LU, Jorgensen PE, Nexo E, Wang P: C-reactive protein and bacterial meningitis: a meta-analysis. Scand J Clin Lab Invest 1998, 58:383-393.
Wacker C, Prkno A, Brunkhorst FM, Schlattmann P: Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis 2013, 13:426-435.
Theodorou VP, Papaioannou VE, Tripsianis GA, Panopoulou MK, Christophoridis EK, Kouliatsis GA, Gioka TM, Maltezos ES, Ktenidou-Kartali SI, Pneumatikos IA: Procalcitonin and procalcitonin kinetics for diagnosis and prognosis of intravascular catheter-related bloodstream infections in selected critically ill patients: a prospective observational study. BMC Infect Dis 2012, 12:247.
Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr TT, Andersen MH, Thornberg KJ, Loken J, Steensen M, Fox Z, et al: Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med 2011, 39:2048-2058.
Cals JW, Hopstaken RM, Butler CC, Hood K, Severens JL, Dinant GJ: Improving management of patients with acute cough by C-reactive protein point of care testing and communication training (IMPAC3T): study protocol of a cluster randomised controlled trial. BMC Fam Pract 2007, 8:15.
Diederichsen HZ, Skamling M, Diederichsen A, Grinsted P, Antonsen S, Petersen PH, Munck AP, Kragstrup J: Randomised controlled trial of CRP rapid test as a guide to treatment of respiratory infections in general practice. Scand J Prim Health Care 2000, 18:39-43.
Gonzales R, Aagaard EM, Camargo CA Jr, Ma OJ, Plautz M, Maselli JH, McCulloch CE, Levin SK, Metlay JP: C-reactive protein testing does not decrease antibiotic use for acute cough illness when compared to a clinical algorithm. J Emerg Med 2011, 41:1-7.
Stolz D, Smyrnios N, Eggimann P, Pargger H, Thakkar N, Siegemund M, Marsch S, Azzola A, Rakic J, Mueller B, Tamm M: Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J 2009, 34:1364-1375.
Hochreiter M, Kohler T, Schweiger AM, Keck FS, Bein B, Von Spiegel T, Schroeder S: Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care 2009, 13:R83.
Kopterides P, Siempos II, Tsangaris I, Tsantes A, Armaganidis A: Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: a systematic review and meta-analysis of randomized controlled trials. Crit Care Med 2010, 38:2229-2241.
Schuetz P, Christ-Crain M, Muller B: Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections-hope for hype? Swiss Med Wkly 2009, 139:318-326.
Schroeder S, Hochreiter M, Koehler T, Schweiger AM, Bein B, Keck FS, Von Spiegel T: Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbecks Arch Surg 2009, 394:221-226.
Tang BM, Eslick GD, Craig JC, McLean AS: Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 2007, 7:210-217.
Li H, Luo YF, Blackwell TS, Xie CM: Meta-analysis and systematic review of procalcitonin-guided therapy in respiratory tract infections. Antimicrob Agents Chemother 2011, 55:5900-5906.